Abstract
Abstract
Background
Aboriginal and Torres Strait Islander peoples are disproportionately impacted by type 2 diabetes. Continuous glucose monitoring (CGM) technology (such as Abbott Freestyle Libre 2, previously referred to as Flash Glucose Monitoring) offers real-time glucose monitoring that is convenient and easy to use compared to self-monitoring of blood glucose (SMBG). However, this technology’s use is neither widespread nor subsidised for Aboriginal and Torres Strait Islander peoples with type 2 diabetes. Building on existing collaborations with a national network of Aboriginal and Torres Strait Islander communities, this randomised controlled trial aims to assess the effect of CGM compared to SMBG on (i) haemoglobin A1c (HbA1c), (ii) achieving blood glucose targets, (iii) reducing hypoglycaemic episodes and (iv) cost-effective healthcare in an Aboriginal and Torres Strait Islander people health setting.
Methods
This is a non-masked, parallel-group, two-arm, individually randomised, controlled trial (ACTRN12621000753853). Aboriginal and Torres Strait Islander adults with type 2 diabetes on injectable therapy and HbA1c ≥ 7.5% (n = 350) will be randomised (1:1) to CGM or SMBG for 6 months. The primary outcome is change in HbA1c level from baseline to 6 months. Secondary outcomes include (i) CGM-derived metrics, (ii) frequency of hypoglycaemic episodes, (iii) health-related quality of life and (iv) incremental cost per quality-adjusted life year gained associated with the CGM compared to SMBG. Clinical trial sites include Aboriginal Community Controlled Organisations, Aboriginal Medical Services, primary care centres and tertiary hospitals across urban, rural, regional and remote Australia.
Discussion
The trial will assess the effect of CGM compared to SMBG on HbA1c for Aboriginal and Torres Strait Islander people with type 2 diabetes in Australia. This trial could have long-term benefits in improving diabetes management and providing evidence for funding of CGM in this population.
Trial registration
Australian and New Zealand Clinical Trials Registry ACTRN12621000753853. Registered on 15th June 2021.
Funder
National Health and Medical Research Council
Publisher
Springer Science and Business Media LLC
Reference52 articles.
1. Islam SMS, Siopis G, Sood S, Uddin R, Tegegne T, Porter J, et al. The burden of type 2 diabetes in Australia during the period 1990–2019: findings from the global burden of disease study. Diabetes Res Clin Pract. 2023;199:110631.
2. Change the future: reducing the impact of the diabetes epidemic. Canberra: Diabetes Australia; 2022.
3. Aboriginal and Torres Strait Islander Health Performance Framework. Tier 1 - health status and outcomes. 1.09 Diabetes. Canberra: Australian Institute of Health and Welfare; 2023.
4. Sinclaire M, Lavallee B, Cyr M, Schultz A. Indigenous peoples and type 2 diabetes: a discussion of colonial wounds and epistemic racism. Can J Diabetes. 2023;47(5):451–4.
5. National Aboriginal and Torres Strait Islander Health Plan 2021–2031. Canberra: Australian Government, Department of Health; 2021. Report No.: DT0002195.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献